● Promotion Period: March 1st 2021 - April 30th 2021
● Eligibility: End clients in Asia Pacific region, excluding Japan.
|TurboKnockout® ES cell targeting Humanized Mice
Because of the characteristics of low immune tolerance to human antigens and easy operation, experimental mice are the most commonly used models for antibody drug development. However, human rejection caused by mouse-derived antibodies seriously affects the safety and efficacy of antibody therapy. Therefore, the humanization of mouse-derived antibodies has become the main battlefield for major pharmaceutical companies to tackle key problems. Currently, the majority of humanized antibody mice are generally unable to introduce human antibody genes to the length of Mb level. To solve these difficulties, it is recommended to use Cyagen’TurboKnockout® gene-editing technology and bacterial artificial chromosome (BAC) recombination.
Bacterial artificial chromosome (BAC) is a low-copy vector that can hold more than 300 kb of foreign DNA. Through BAC recombination, larger genes and regulatory sequences can be introduced - which is closer to the expression pattern of endogenous genes. Based on traditional embryonic stem (ES) cell targeting techniques, TurboKnockout® provides accurate gene modifications, stable integration, no off-target risks, and can achieve LFKI (up to 300kb) through bacterial artificial chromosome (BAC) recombination. Importantly, the project cycle can be significantly shortened through multi-step BAC reorganization at the ES cell level. Compared to CRISPR/Cas9, TurboKnockout® is free of patent disputes and is the technique of choice for new drug development projects. For consultation and order, please call 86 20-31601779 or email email@example.com.
* Click the button to view the targeting vector design & construction.
Large fragment gene-editing:
Limited by the capacity of DNA cloning vectors, foreign gene fragments integrated into genetically modified animals are usually less than 30kb. At this size limitation, key elements in regulating gene activity are often lost. BAC can accommodate foreign DNA of more than 300 kb. By introducing larger genes and regulatory sequences through BAC modification, this allows greater control over the expression pattern of genes.
No off-target effects:
TurboKnockout® is based on traditional ES cell targeting techniques; it can be used for complex gene knockouts for mice, providing models with accurate genetic modification, 100% germ line transmission, and no off-target effects.
No risk of patent infringement:
Compared with CRISPR/Cas9 techniques, TurboKnockout® is free of patent disputes and is the technique of choice for new drug development projects.
Founders as fast as 6 months thanks to two innovations that eliminate two generations of breeding: 1) super competent ES cell line generates 100% ESC-derived founders, avoiding the‘chimera’phase; and 2) a self-removing Neo selection cassette that circumvents the need to breed to Flp deleter mice. In addition, multi-step BAC reorganization by TurboKnockout® at the ES cell level can shorten the production cycle.